{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"9"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"19"}],"units":"Participants"}],"title":"ACC"},{"categories":[{"measurements":[{"groupId":"OG000","value":"4"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"17"}],"units":"Participants"}],"title":"Non-ACC"}],"denoms":[{"counts":[{"groupId":"OG000","value":"36"}],"units":"Participants"}],"description":"Number of patients who had Stable disease for more than or equal to 6 months together in both Adenoid cystic carcinoma (ACC) and non-adenoid cyctic carcinoma (non-ACC)","groups":[{"description":"Patients receive oral lapatinib once daily on days 1-28. Courses repeat every 28 days in the absence of unacceptable toxicity or disease progression.\n\nlapatinib ditosylate: Given orally\n\nlaboratory biomarker analysis: Correlative studies","id":"OG000","title":"Treatment (Lapatinib Ditosylate)"}],"paramType":"NUMBER","populationDescription":"36 assessable participants, 19 with ACC and 17 with non-ACC.","reportingStatus":"POSTED","timeFrame":"6 months","title":"Rate of Stable Disease","type":"SECONDARY","unitOfMeasure":"participants"}